Crohn’s disease
Takeda and TiGenix’s Alofisel becomes first donor-derived stem cell therapy approved in Europe
March 26, 2018Sales and Marketing Crohn’s disease, EU, Europe, European Commission, Takeda, TiGenix, crohn's disease, pharma
The European Commission has awarded approval to Takeda and TiGenix’s allogeneic expanded adipose-derived stem cell (eASC) therapy Alofisel (darvadstrocel) for …
Janssen’s Stelara shows improvement in Crohn’s symptoms within one week, new findings reveal
October 30, 2017Manufacturing and Production, Research and Development Crohn’s disease, Janssen, Stelara, crohn's disease, pharma
Janssen has unveiled new data on Stelara (ustekinumab) in the treatment of patients with moderately to severely active Crohn’s disease …
Switching Crohn’s patients to biosimilar Inflectra from Remicade is safe and effective, Pfizer says
October 30, 2017Research and Development, Sales and Marketing Crohn’s disease, Pfizer, Remicade, crohn's disease, inflectra, pharma
Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to …
NICE recommends Janssen’s first-of-its-kind Crohn’s drug Stelara
May 3, 2017Research and Development, Sales and Marketing Crohn’s disease, Janssen, NICE, Stelara, crohn's disease
Janssen has announced that it has secured recommendation from NICE for Stelara (ustekinumab) in the indication of moderately to severely …
Celgene trial displays promising results for Crohn’s disease alternative treatment
October 17, 2016Sales and Marketing Celgene, Celgene corporation, Crohn’s disease, clinical trials, crohn's disease, phase I, trial
Celgene International, part of Celgene Corporation, has released the results from a Phase Ib trial showing improvement in patients suffering …
AstraZeneca agrees $250 million licensing agreement with Allergan
October 3, 2016Sales and Marketing Allergan, AstraZeneca, Crohn’s disease, MEDI2070, MedImmune, crohn's disease
Allergan has entered into a licensing agreement with MedImmune, of AstraZeneca, for the global rights of MedI2070, a synthetic antibody. …
Janssen says its Stelara maintained clinical remission in Crohn’s disease in Phase III trials
May 26, 2016Research and Development, Sales and Marketing Crohn’s disease, Janssen, Stelara, crohn's disease, drug trial
Janssen said its maintenance therapy for Crohn’s disease showed remission for patients in late-stage trials. The company said a significant …
J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease
March 18, 2016Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease
Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …
TiGenix says additional data for stem cell product affirms safety profile
March 9, 2016Research and Development Crohn’s disease, TiGenix, crohn's disease, drug trial
Belgian biotech firm TiGenix said the results of a 52-week follow-up study of its trial drug for a stem-cell condition …
Janssen, Enterome and Kymab in research collaborations
January 7, 2016Research and Development Crohn's, Crohn’s disease, Enterome, Janssen, MD Anderson, alliance, antibodies, collaboration, crohn's disease, immuno-oncology, kymab, research
Several pharma companies have announced new collaborations, to research potential new drugs for Crohn’s disease, and immuno-oncology treatments for cancer. …
Janssen submits Stelara for EU approval for Crohn’s
December 9, 2015Sales and Marketing Crohn’s disease, EMA, European Medicines Agency, Janssen, Stelara, crohn's disease, ustekinumab
Janssen today announced that it has submitted an application to the European Medicines Agency, seeking approval of Stelara in Crohn’s …
Encouraging late-stage results for Stelara in Crohn’s disease
October 21, 2015Research and Development, Sales and Marketing Crohn’s disease, Janssen, Stelera, crohn's disease, ustekinumab
Janssen is planning new regulatory submissions for Stelera after Phase III data found it improved responses and remission rates in …
Celgene to acquire Receptos in $7.2bn deal
July 15, 2015Sales and Marketing Celgene, Crohn's, Crohn’s disease, Receptos, acquisitions, crohn's disease, mergers, multiple sclerosis, ozanimod, relapsing multiple sclerosis, ulcerative colitis
Celgene has boosted its immune and inflammatory disease pipeline with the purchase of the biopharma company Receptos for $7.2 billion. …
NICE u-turns on Entyvio for Crohn’s disease
July 10, 2015Medical Communications, Sales and Marketing Crohn's, Crohn’s disease, Entyvio, Millenium, NICE, Takeda, funding
NICE has performed a u-turn and recommended drug treatment Entyvio for Crohn’s disease for routine NHS funding.In final draft guidance …
TiGenix and Lonza partner on stem cell manufacturing
February 13, 2015Manufacturing and Production, Sales and Marketing Crohn’s disease, Lonza, Stem cells, TiGenix, crohn's disease, eascs, manufacturing, spa
Stem cell therapy developer TiGenix has enlisted the help of biologics manufacturer Lonza to produce its medicine Cx601 for late-stage …
Latest content
Five Facts about cardiovascular disease
